The Effect of TLR4 Inhibition in Obese and Type 2 Diabetic Subjects

Phase 2 Terminated 15 enrolled The University of Texas Health Science Center at San Antonio

RandomizedCrossoverQuadruple-blindTreatment

Summary

To determine whether pharmacologic inhibition of Toll-like receptor 4 (TLR4) with eritoran for injection (E5564) will reduce inflammation and improve glucose metabolism in insulin resistant (obese and T2DM) subjects.

Timeline

Start: 2015-01
Primary completion: 2018-09
Completion: 2018-09

Publications

Liang H, Sathavarodom N, Colmenares C, Gelfond J, Espinoza SE, Ganapathy V, Musi N. Effect of acute TLR4 inhibition on insulin resistance in humans. J Clin Invest. 2022 Nov 1;132(21):e162291. doi: 10.1172/JCI162291.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Eritoran	Small molecule	12 mg	Intravenous

Indications

No indication recorded.